The key to success is in our people
Our team is comprised of true innovators in the field who are passionate about changing the way we treat GI diseases.
Mark C. McKenna
President & CEO, Board Member
Mr. McKenna serves as President, CEO, and member of the Board of Directors of Prometheus Biosciences. Since joining in 2019, he has executed multiple value-generating business development deals, and raised more than $350M+ in capital including an initial public offering in 2021. Prior to joining Prometheus Biosciences, Mr. McKenna was a corporate officer of Bausch Health Companies, serving as President of the wholly owned subsidiary, Salix Pharmaceuticals. Responsible for successfully turning around the gastrointestinal business, Mr. McKenna led the team through a series of key strategic acquisitions and new product launches, and delivered strong operating performance, with revenue increasing from $950M to over $2B during his tenure. Prior to joining Salix, Mr. McKenna spent more than a decade with Bausch + Lomb, most recently as Senior Vice President/General Manager of its U.S. Vision Care business. Prior to Bausch + Lomb, he held several roles of increasing responsibility at Johnson & Johnson. Mr. McKenna serves as the Chairman of the Board of Prometheus Labs, and holds a B.S. in Marketing from Arizona State University and an MBA from Azusa Pacific University.
Laurens Kruidenier, Ph.D.
Chief Scientific Officer
Laurens Kruidenier, Ph.D. has served as our Chief Scientific Officer since May 2019, and previously served as our SVP of Research from July 2018 to May 2019. He has over 25 years of experience in IBD discovery research, both in academic settings as well as in the life sciences industry. Dr. Kruidenier was Vice President of Discovery at Second Genome Inc. from July 2017 to July 2018, where he was responsible for a portfolio of microbiome programs. Previously, Dr. Kruidenier served as Head of GI Immunology Research at Takeda Pharmaceuticals from January 2015 to June 2017. Dr. Kruidenier also held various positions at GlaxoSmithKline plc. starting in April 2006, including most recently as Head of Biology of the Protein Degradation Unit from January 2013 to January 2015. Dr. Kruidenier holds an M.Sc. in Medical Biology from Utrecht University in the Netherlands and a Ph.D. in Experimental Gastroenterology from Leiden University in the Netherlands.
Allison Luo, M.D.
Chief Medical Officer
Allison Luo, M.D. has served as our Chief Medical Officer since August 2018. Prior to that, Dr. Luo concurrently served as Chief Medical Officer at Oppilan Pharma and Escalier Pharma since March 2017, and as Senior Vice President of Clinical Development for Gastroenterology at Progenity Inc. since June 2017. Before that, Dr. Luo was Vice President of Clinical Development at Ophthotech Corp., now Iveric bio, Inc., since September 2015. She was an Executive Director at Bristol Myers Squibb Company from September 2006 to October 2014, where she was responsible for inflammatory bowel disease and led the Phase 3 program for Orencia (abatacept) and the Phase 2 programs for eldelumab (anti-IP10 antibody) for ulcerative colitis and Crohn’s disease. Earlier in her career, Dr. Luo was a Medical Director at Abbott Laboratories where she submitted the Japanese NDA for Humira in rheumatoid arthritis and developed the clinical trial protocols for Humira in ulcerative colitis. Dr. Luo holds a B.S. in Biochemistry and an M.D. from Northwestern University.
Keith W. Marshall, Ph.D.
Chief Financial Officer
Keith W. Marshall, Ph.D., has served as our Chief Financial Officer since August 2020. Previously, he served as Executive Vice President, Chief Operating Officer, and Chief Financial Officer of Conatus Pharmaceuticals Inc., now Histogen, Inc., from August 2017 to May 2020. Dr. Marshall served as Chief Financial Officer and Head of Corporate Development at Torque Therapeutics Inc. from 2015 to 2017, where his responsibilities included finance, operations, human resources, corporate strategy, and business development. He served as Managing Director and Advisor in Healthcare Investment Banking from 2012 to 2014 at GCA Savvian Advisors, where he provided strategic counsel to healthcare companies, and continued from 2014 to 2015 at TAG Healthcare Advisors under an alliance with GCA Savvian. Previously, Dr. Marshall was Managing Director from 2011 to 2012 at Sagent Advisors and Managing Director, Co-founder, and Chief Financial Officer from 2008 to 2011 at Montgomery, Marshall Healthcare Partners. Dr. Marshall began his banking career at JPMorgan.
Dr. Marshall holds an A.B. in Biology from Washington University in St. Louis, a Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco, and an M.B.A. with concentrations in Finance, Strategy, and Entrepreneurship from the University of Chicago Booth School of Business.
Olivier Laurent, Ph.D.
Chief Technology Officer
Olivier Laurent, Ph.D., has served as our Chief Technology Officer since September 2020. Before joining our company, Dr. Laurent served from October 2019 to September 2020 as Chief Scientific Officer at Intrepida Bio, an immuno-oncology company focused on developing novel antibodies for the treatment of solid tumors. Prior to this position, Dr. Laurent was Chief Scientific Officer at Dauntless Pharmaceuticals, a company working on novel formulations of octreotide for the treatment of metabolic and oncology indications, from July 2015 to October 2019. Before joining Dauntless Pharmaceuticals, Dr. Laurent held positions of increasing responsibilities at Sanofi S.A., Bayer AG, Genentech, Inc., Pfizer Inc., CovX (acquired by Pfizer in 2008) and Ambrx (acquired by a Chinese consortium in 2015). Dr. Laurent holds a Ph.D. in Cell Biology from the University of Grenoble, an M.S. in Molecular and Cell Biology earned in a dual program from the University of Grenoble and the University of Lyon, and a B.S. in Molecular and Cell Biology from the University of Lyon.
Chief Operating Officer
Mark Stenhouse has served as our Chief Operating Officer since March 2021. Previously, Mr. Stenhouse served as a member of our Board of Directors from April 2018 to October 2020 and then as an advisor to our company through February 2021. Mr. Stenhouse served as General Manager, Screening at Exact Sciences Corporation from November 2019 to January 2021 and as an advisor to the company through February 2021. Mr. Stenhouse served as President, Cologuard at Exact Sciences Corporation from April 2018 until November 2019. From October 2016 until March 2018, Mr. Stenhouse served as Vice President, U.S. Immunology at AbbVie, Inc., where he oversaw U.S. expansion into the immunology marketplace. From April 2010 until September 2016, Mr. Stenhouse served as Vice President and Vice President/General Manager, U.S. Immunology-Gastroenterology Franchise at AbbVie. From September 2006 through March 2010, Mr. Stenhouse held various senior management, marketing, and sales positions within Abbott Laboratories’ U.S. Immunology division. Mr. Stenhouse holds a B.B.A. from the College of Charleston.
Chief People Officer
Ms. Nori Ebersole has served as Chief People Officer since April 2021. Prior to joining Prometheus Biosciences, Ms. Ebersole served as EVP & Chief Human Resources Officer for Urovant Sciences, Inc (Nasdaq: UROV) from 2017 to 2021 until its $681M enterprise value take private merger with Sumitomo Dainippon at a 96% premium. In this role, she was instrumental in their 2018 IPO, building the board, executive, and senior leadership teams. She also led the development and execution of their diversity, equity and inclusion strategy, employment brand, talent acquisition, mission, vision and values strategies, and the build of the field sales and market access teams for commercial launch. Prior to Urovant, she was the Chief Human Resources Officer at Paul Hastings, LLP from 2015 to 2017. Ms. Ebersole also served 18 years at Allergan Inc., from 1994 to 2015, until their sale to Actavis for $70.5B. Ms. Ebersole earned a B.S. in Business Administration from the University of Southern California Marshall School of Business and serves on the board of Big Brothers, Big Sisters of Orange County.
Timothy K. Andrews
Timothy K. Andrews has served as our General Counsel since November 2020. From October 2016 through December 2019, he served as General Counsel and Secretary for Sienna Biopharmaceuticals, Inc., a publicly traded, clinical-stage biotech company. Mr. Andrews served as the Head of Legal at Whitecap Biosciences LLC, a start-up company founded by former Allergan, Inc. research and development executives, from July 2015 to October 2016. Mr. Andrews served as Senior Corporate Counsel and Assistant Secretary at Allergan, Inc. from 2011 through 2015, where he had legal responsibility for U.S. and international business development transactions, including acquisitions, licensing, and partnerships, as well as corporate governance and securities law compliance. From 2006 to 2011, Mr. Andrews was a corporate attorney at Latham & Watkins LLP. He was previously a Business Analyst at Deloitte Consulting. Mr. Andrews holds a B.A. in Political Economy from the University of California, Berkeley and a J.D. from Loyola Law School, Los Angeles.
Chief Business Officer
Mr. Chris Doughty serves as our Chief Business Officer. Mr. Doughty joined Prometheus in February 2021 from Strata Oncology, a precision oncology company, where he served as Vice President of Strategy and Business Development and led the organization’s pharma business development efforts. Before pursuing opportunities focused in precision medicine, Mr. Doughty began his career in strategy consulting, most recently serving as an Engagement Manager at McKinsey & Company and also having spent time at Kaufman Hall and Deloitte. Mr. Doughty holds an MBA from the University of Michigan’s Ross School of Business and a B.S.E. in Industrial & Operations Engineering from the College of Engineering at the University of Michigan.
Senior Vice President, Finance
Ms. Vika Brough has over 15 years of experience in public and private accounting roles. She started her career as an auditor at Ernst & Young Assurance practice in San Diego, California. During her 10 years as an auditor, Ms. Brough served many multinational public and private clients in life science, medical devices, and technology industries. After Ernst & Young, Ms. Brough was Head of Finance at Human Longevity, Inc., a genomics-based company in San Diego, where she oversaw financial planning, accounting, treasury, and procurement functions. Ms. Brough graduated from San Diego State University with a Bachelor of Accounting degree.